All-trans retinoic acid: tolerance and biologic effects in myelodysplastic syndrome. J Clin Oncol 1993 Aug;11(8):1489-95
Date
08/01/1993Pubmed ID
8336187DOI
10.1200/JCO.1993.11.8.1489Scopus ID
2-s2.0-0027227770 (requires institutional sign-in at Scopus site) 58 CitationsAbstract
PURPOSE: We conducted a study to evaluate the tolerance to and biologic effects of all-trans retinoic acid in patients with myelodysplastic syndrome.
PATIENTS AND METHODS: Thirty-nine patients with myelodysplastic syndrome were treated with oral all-trans retinoic acid for 6 weeks. Dose levels were 10, 25, 50, 100, 150, 200, and 250 mg/m2/d. At least three patients were treated on each dose level.
RESULTS: The most common side effects were mucocutaneous dryness and erythema, and hypertriglyceridemia. Dose-limiting side effects were diverse and included dermatitic problems, sensorineural hearing loss, headaches, nausea and vomiting, myalgias, and dyspnea. The maximum-tolerated dose was 150 mg/m2/d. Only one response was seen among 29 patients considered assessable for response.
CONCLUSION: All-trans retinoic acid can be safely administered to patients at doses up to 150 mg/m2/d for 6 weeks. However, as administered in this study, this compound does not appear to have significant activity in myelodysplastic syndromes.
Author List
Kurzrock R, Estey E, Talpaz MAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Administration, OralAdult
Aged
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes
Treatment Outcome
Tretinoin